Literature DB >> 8627645

Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation.

D Bartsch1, D W Shevlin, M P Callery, J A Norton, S A Wells, P J Goodfellow.   

Abstract

Entities:  

Mesh：

Year:  1996        PMID： 8627645     DOI： 10.1093/jnci/88.10.680

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  6 in total

Review 1.  The CDKN2A (p16) gene and human cancer.

Authors:  W D Foulkes; T Y Flanders; P M Pollock; N K Hayward
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

2.  p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb.

Authors:  Berthold Gerdes; Annette Ramaswamy; Andreas Ziegler; Sven A Lang; Michael Kersting; Renate Baumann; Anja Wild; Roland Moll; Matthias Rothmund; Detlef K Bartsch
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

3.  Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer.

Authors:  Joon Jeong; Young Nyun Park; Joon Seong Park; Dong-Sup Yoon; Hoon Sang Chi; Byong Ro Kim
Journal:  Yonsei Med J       Date:  2005-08-31       Impact factor: 2.759

4.  Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase.

Authors:  Oddbjørn Straume; Johanna Smeds; Rajiv Kumar; Kari Hemminki; Lars Andreas Akslen
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

5.  K-ras oncogene mutations indicate malignancy in cystic tumors of the pancreas.

Authors:  D Bartsch; D Bastian; P Barth; A Schudy; C Nies; O Kisker; H J Wagner; M Rothmund
Journal:  Ann Surg       Date:  1998-07       Impact factor: 12.969

6.  Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma.

Authors:  Jyotika Attri; Radhika Srinivasan; Siddhartha Majumdar; Bishan Dass Radotra; Jaidev Wig
Journal:  BMC Gastroenterol       Date:  2005-06-28       Impact factor: 3.067
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.